MedTrace Logo

Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)

NCT02039986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2018-12-14

No results posted yet for this study

Summary

This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation. Investigators hypothesize that treatment with ivacaftor improves insulin secretion in individuals with CF.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Andrea Kelly, MD, MSCE · Children's Hospital of Philadelphia

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-06
Primary Completion
2016-10-11
Completion
2016-10-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02039986 on ClinicalTrials.gov